<DOC>
	<DOCNO>NCT01948817</DOCNO>
	<brief_summary>This open label , single arm , multicenter study . The study include follow phase . A screening phase last 4 week determine patient eligibility . This phase follow 24 week Open label treatment phase . The study treatment define deferasirox 20mg/kg BID 9Twice day ) . Serum Ferritin Levels MRI ( Magmetic Resonance Imaging ) LIC ( Liver Iron Concentration ) measure evaluate response BID .</brief_summary>
	<brief_title>Deferasirox BID ( Twice Day ) Transfusion Dependent Thalassemia Patients With Inadequate Response High Doses</brief_title>
	<detailed_description>Study treatment define deferasirox 20 mg/kg BID . The study treatment duration 24 week . After baseline visit , patient visit occur weekly first month key safety parameter need perform weekly first month treatment every 4 week thereafter week 24 End Treatment ( EOT ) . Patients first dose study treatment Visit 3 . Safety assessment routinely perform include collection AEs ( Adverse Events ) , SAEs ( Serious ADverse Events &lt; , vital sign , physical examination , ECG ( Electrocardiograph ) , hematological biochemistry assessment . Patients continue therapy intolerable toxicity , patient decision 24 week treatment duration point End Treatment ( EOT ) visit perform End Treatment CRF ( Case Report Form ) complete . 30 day Safety follow-up Patients discontinue study drug complete study schedule visit soon possible , time assessment list final visit perform . At minimum , patient discontinue study treatment , include refuse return final visit , contact safety evaluation 30 day follow last dose study drug . All patient must follow AEs SAEs may occur discontinuation study treatment . The safety follow-up visit take place 30 day last dose study drug .</detailed_description>
	<mesh_term>Thalassemia</mesh_term>
	<mesh_term>Deferasirox</mesh_term>
	<criteria>Written informed consent must obtain prior screen procedure Male female age ≥ 2 year screen Patients transfusion dependent thalassemia Patients confirm inadequate responder deferasirox &gt; 35 mg/kg QD treat QD least 6 month Regular transfusion indicate blood requirement ≥ 8 blood transfusion per year screen Serum ferritin level &gt; 2,500 ng/mL screen ( two consecutive value least 2 week apart ) One SF measurement &gt; 2,500 ng/mL 6 9 month prior study enrollment Three SF measurement &gt; 2,500 ng/mL , perform least 3 week apart , 6 month treatment QD dosing deferasirox prior study enrollment The average two screen SF value ( collect 2 week apart ) must show decrease 6 9 month SF value take prior study enrollment The average two screen SF value ( collect 2 week apart ) must show decrease three SF value obtain 6 month deferasirox QD treatment prior study enrollment LIC ≥ 7 mg Fe/g dw measure screening visit , ( value use baseline measurement Patients intolerant &gt; 35 mg/kg/day QD deferasirox 6 month prior study enrollment Patients mean level ALT &gt; 5 x ULN Patients serum creatinine upper limit normal ( ULN ) Significant proteinuria indicate urinary protein/creatinine ratio &gt; 0.5 ( mg/mg ) Creatinine clearance ≤ 60 ml/min Chronic hepatitis B infection , active hepatitis C infection History positive HIV test Uncontrolled systemic hypertension Patients participate another clinical trial receive systemic investigational drug within past 4 week topical investigational drug within past 7 day screen History noncompliance medical regimens patient consider potentially unreliable and/or cooperative , unwilling unable comply protocol History hypersensitivity study drug excipients Significant medical condition interfere ability partake study ( e.g . systemic uncontrolled hypertension , unstable cardiac disease control standard medical therapy , systemic disease ( cardiovascular , renal , hepatic etc . ) History drug alcohol abuse within 12 month prior enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Thalassemia</keyword>
</DOC>